Исследование значимости опухолеассоциированных маркеров UBC, Tu M2-PK и TPS в онкоурологии
Диссертация
Исследован уровень нового опухолевого маркера Tu М2-РК в плазме крови онкологических и неонкологических больных разных клинических групп. Установлено, что оптимальный дискриминационный уровень этого маркера составляет 17 Ед/мл, что обеспечивает его диагностическую чувствительность у больных раком почек в целом 76,0% при специфичности 95,4% по отношению к донорам и 81,6% по отношению к пациентам… Читать ещё >
Список литературы
- Гринстейн Б., Гринстейн А. Наглядная биохимия. // ГЭОТАР Медицина. -2000. с.86−88.
- Ленинжер А. Биохимия. // Москва. 1974. — с.378.
- Лопаткин Н.А., Даренков А. Ф., Игнашин Н. С. Ультразвуковая диагностика новообразований мочевого пузыря. // Урология и нефрология. 1983. — № 4. -с.3−7.
- Лопаткин Н.А., Камалов А. А., Кудрявцев Ю. В. и др. Флюоресцентная диагностика рака мочевого пузыря. // Урология. 2000. — № 4. — с.3−6.
- Мазо Е.Б., Беличенко О. И., Шария М. А. и др. Магнитно-резонансная томография в диагностике и стадировании рака мочевого пузыря. // Урология. -2000.-№ 16.-с. 43−45.
- Мационис А.Э., Матвеенко А. А., Медведева Л. А. и др. Поверхностный рак мочевого пузыря. // Матер. 4-й Всеросс.конф. Москва 2001. — с.30−38.
- Переверзев А.С., Петров С. Б. Опухоли мочевого пузыря. // Харьков. 2002. -с.53−95.
- Чиссов В.И., Дарьялова С. Л. Избранные лекции по клинической онкологии. // Москва. 2000. — с.618−619.
- Чиссов В.И., Старинский В. В., Петрова Г. В. Злокачественные новообразования в России в 2003 году (заболеваемость и смертность).// Москва. 2005. -с.5−7.
- Aulitzky W., Gastl G., Nachbaur K. et al. Interferon-gamma for the treatment of metastatic renal cancer: dosedependet stimulation and downregulation of beta-2 microglobulin and neopterin responses. // Immunobiology. 1987. — Vol.176 (1−2). -P.85−95.
- Aulitzky W., Grosse-Wilde H., Westhoff U. et al. Enhanced serum levels of soluble HLA class I molecules are induced by treatment with recombinant interferon-gamma. // Clin Exp Immunology. 1991. — Vol.86 (2). — P.236−239.
- Bashar H., Urano Т., Fukuta K. et al. Plasminogen activators and plasminogen activator inhibitor 1 in urinary tract cancer/ // Urol. Int. 1994. — Vol.52 (1). — P.4−8.
- Boman H., Hedelin H., Holmang S. Four bladder tumor markers have a disappointingly low sensitivity for small size fnd low grade recurrence. // J Urology. 2002. — Vol.167. — P.80−83.
- Boman H., Hedelin H., Holmang S. Urine tissue-polypeptide-specific antigen (TPS) as a marker for bladder cancer. // J Scandinavian Urology and Nephrology. -2001.-Vol.35.-P.270−274.
- Boman H., Hedelin H., Jacobsson S. et al. Newly diagnosed bladder cancer: the relationship of initial symptoms, de microhematuria and tumor marker status. // J Urology. 2002. — Vol.168. — P.1955−1959.
- Brinck U., Eigenbrodt E., Oehmke M. et al. L- and М-2-pyruvate kinase expression in renal cell carcinomas and their metastases. // Virchows Arch. 1994. — Vol.424 (2).- P.177−185.
- Brown F. Urine cytology. It is the gold standard for screening? // J Urologic Clinics of North America. 2000. — Vol.27. — P.25−37.
- Chang С., Wu H., Yen R. et al. Tissue polypeptide specific antigen (TPS) as a tumor marker in renal cell carcinoma. // Anticancer Research. 2002. — Vol.22 (5). — P.2949−2950.
- Chong Т., Cheng C. The role of the bladder tumour antigen test test in the management of gross haematuria. // Singapore Medical J. 1999. — Vol.40. P.578−580.
- Del Nero A., Esposito N., Curraz A. et al. Evaluation of urinary level of NMP 22 as a diagnostic marker for stage pTa-pTl bladder cancer: comparison with urinary cytology and BTA test. // Eur Urol. 1999. — Vol.35. — P.93−97.
- Dolz M., Drakopoulos A., Aurich B. et al. Trasrectal prostatosonography. Follow-up in prostate cancer therapy. // J Urology Nephrology. 1985. — Vol.78. — P.465−474.
- Dosquet C., Coudert M., Lepage E. et al. Are angiogenic factors, cytokines and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma. // Clin Cancer Res. 1997. — Vol.3. — P.2451−2458.
- Echenique J., Graham S. Significance of lipid-associated sialic acid and CA 19−9 as tumor markers for renal cell carcinoma. // J Urology. 1988. — Vol 32 (5). — P.397−400.
- Fateh-Moghadam A., Stieber P. Sensible use of tumor markers. // Switzerland: Springer Verlag.-Elitiones Roche. 1993. — P.78.
- Fritz H. Evidence in Advanced disease: the challenge for new therapies. // European Urology Supplements. 2002. — Vol.1. — P. 11−16.
- Fujii Y., Okuno Т., Masuda M. et al. A case of transitional cell carcinoma of renal pelvis with an extremely high serum carcinoembryonic antigen level. // Hyniokika Kiyo. 1992. — Vol.38 (1). — P.55−59.
- Gershkevitsh E., Rosenberg I., Dearnaley D. Bone marrow doses and leukaemia risk in radiotherapy of prostate cancer. // Radiotherapy Oncology. 1999. — Vol.53. -P.189−197.
- Gerwenka H., Aigner R., Bacher H. et al. Tu M2-PK (Pyruvate Kinase Type Tumor M2), CA 19−9 and CEA in patients with benign, malignant and metastasizing Pancreatic lesions. // Anticancer Research. 1999. — Vol.19. — P.849−852.
- Gliffioen A., Damen C., Martinotti S. et al. Endothelial intercellular adhesion molecule-1 expression is suppressed in human malignancies: the role of angiogenic factors. // Cancer Research. 1996. — Vol.56 (5). — P. l 111−1117.
- Gohji K., Ishii M., Nagata H. et al. Serum basic fetoprotein in patients with renal cell carcinoma. // Cancer. 1990. — Vol.65 (6). — P.1405−1411.
- Grankvist K., Ljunberg В., Rasmuson T. Evaluation of five glycoprotein tumor markers (СБА, CA-50, CA 19−9, CA 125, CA 15−3) for the prognosis of renal cell carcinoma. // Int J Cancer. 1997. — Vol.74 (2). — P.233−236.
- Gregersen В., Mommsen S., Svanholm H. Bladder tumor antigen test versus urinary cytology in patients with bladder tumors. // J Ugeskrift Laeger. 1999. -Vol. 161.-P. 2071−2073.
- Gutierrez Banos J., Martin Garcia В., de Diego Rodriguez E. et al. The BTA stat test in the follow-up for bladder cancer. // J Archivos Espanoles de Urologia. -1999.-Vol.52.-P.856−861.
- Gutierrez Banos J., Rebollo Rodrigo M., Antolin Juarez F. et al. Comparative study of BTA stat test, NMP 22 fnd cytology in the diagnosis of bladder cancer. // J Archivos Espanoles de Urologia. 2000. — Vol.53. — P.21−27.
- Hardt P., Ngoumou В., Rupp J. et al. Tumor M2-pyruvate kinase: a promising tumor marker in the diagnosis of gastro-interstinal cancer. // Anticancer Research. -2000. Vol.20. — P.4965−4968.
- Heicappell R., Podlinski J., Buszello H. et al. Cell surface expression and serum levels of intercellular adhesion molecule-1 in renal cell carcinoma. // Urology Research. 1994. — Vol.22 (1). — P.9−15.
- Heicappell R., Schostak M., Muller M. et al. Evaluation of urinary bladder cancer antigen as a marker for diagnosis of transitional cell carcinoma of the urinary bladder // Scand J Clin Lab Invest. 2000. — Vol.60. — P.275−282.
- Heicappell R., Wetting I., Schostak M. et al. Quantitative detection of human complement factor H-related protein in transitional cell carcinoma of the urinary bladder. // J European Urology. 1999. — Vol.35. P.81−87.
- Heise J., Dizol P. Tumor markers: Their uses and significance in clinical practice. // Boehringer Mannheim. 1991. — P.85.
- Hemmerlein В., Scherbening J., Kugler A. et al. Expression of VCAM-1, ICAM-1, E- and P-selectin and tumor-associated macrophages in renal cell carcinoma. // Histopathology. 2000. — Vol.37 (1). — P.78−83.
- Hernandez-Cerceno M., Gonzalez de Buitrago J., Navajo J. Cetokeratins (UBC and CYFRA 21−1) and nuclear matrix proteins (NMP 22) as urine tumor markers in the diagnosis of the bladder cancer. // J Medicina Clinica. 2000. — Vol.114. — P.361−366.
- Hobarth H., Hallas A., Steiner G. et al. Circulating immune markers in advanced renal cell carcinoma during immunotherapy with interferon gamma. // Urology Research. 1996. — Vol.24 (2). -P.101−106.
- Hobarth K., Hallas A., Kramer G. et al. Tissue polypeptide specific antigen in renal cell carcinoma. // J European Urology. 1996. — Vol.30 (1). — P.89−95.
- Hoffmann R., Franzke A., Buer J. et al. Prognostic impact of in vivo soluble cell adhesion molecules in metastatic renal cell carcinoma. // Br J Cancer. 1999. -Vol.79 (11−12). — P. 1742−1745.
- Imamura M., Inoue K., Megumi Y. et al. Clinical evaluation of urinary basic fetoprotein and the BTA test for detection of bladder cancer. // Hinyokika Kiyo. -2000. Vol.46. — P.705−709.
- Iori F., De Matteis A., Frioni D. et al. Role of urinary cytology in the study of bladder cancer. Comparison with the BTA test. // J Arch Italiano Di Urologia, Andrologia. 1999. — Vol.71. — P.279−282.
- Jancovic D., Nastic-Miric D., Radovanovic Z. et al. Proteinyria and beta 2-microglobulinuria in patients with tumors of the renal pelvis and ureter and healthy persons from areas of endemic nephropathy. // Uroi Nefrol (Moskow). 1989. -Vol.6.-P.13−14.
- Kallio J., Tammela Т., Marttinen A. et al. Soluble immunological parameters and early prognosis of renal cell cancer patients. // J Exp Clin Cancer Research. 2001. -Vol.20 (4). -P.523−528.
- Kastelan M., Kovacic K., Tarle R. et al. Analisis of NK cell activity, lymphocite reactivity to mitogens and serotest PSA and TPS values in pstients with primary and disseminated prostate cancer. // Anticancer Research. 1997. — Vol.17. — P. 16 711 675.
- Kazama Т., Katayama Т., Yamazaki N. Serum and urinary tissue polypeptide antigen (TPA) in patients with urological cancer. // Hinyokika Kiyo. 1985. -Vol.31 (12). — P.2113−2119.
- Koenig F., Jung K., Schnorr D. et al. Urinary markers of malignancy. // J Clin Chim Acta. 2000. — Vol.297. — P.191−205.
- Kraljic I., Kovacic K., Tarle M. Serum TPS, PSA and PAP values in relapsing stage D2 adenocarcinoma prostate. // Urology Research. 1994. — Vol.22. — P.329−332.
- Kramer G., Steiner G., Madersbacher S. et al. Serial tissue polypeptide-specific antigen determination in the followup of hormone treated carcinoma of the prostate. // J Urology. 1997. — Vol.158. — P. 1446−1451.
- Kramer G., Steiner G., Sokol P. et al. Local intratumoral tumor necrosis factor-alpha and systemic IFN-alpha 2 in patients with locally advanced prostate cancer. // J Interferon Cytokine Research. 2001. — Vol.21. — P.475−484.
- Krupski Т., Moskaluk C., Boyd J. et al. A prospective pilot evaluation of urinary and immunohistochemical markers as predictors of clinical stage of urothelial carcinoma of the bladder. // J Bju Int. 2000. Vol.85. — P.1027−1032.
- Kruse R., Geilenkeuser W., Rohle G. et al. Overview Quality control of tumor marker assay. // J Biological Markers. 1998. — Vol.13. — P.238−240.
- Kusama K., Asano M., Moro I. et al. Tumor markers in human renal cell carcinoma. // Tumour Biology. 1991. — Vol.12 (4). — P. 189−197.
- Leyh H., Marberger M., Conort P. et al. Comparison of the BTA stat test with voided urine cytology and bladder wash cytology in the diagnosis and monitoring of bladder cancer. // J European Urology. 1999. — Vol.35. — P.52−56.
- Linderkamp C., Floken W., Schulz E. et al. Renal cell cancer in childhood. // Monatsschr Kinderheilkd. 1992. — Vol.140 (11). — P.799−802.
- Luffner D., Mesterharm J., Akrivakis C. et al. Tumor type M2 Pyruvate Kinase expression in advanced Breast Cancer. // Anticancer Research. 2000. — Vol.20. -P.5077−5082.
- Lukkonen A., Lintula S., von Boguslawski K. et al. Tumor-associated trypsin inhibitor in normal and malignant renal tissue and in serum of renal-cell carcinoma patients. // Int. J Cancer. 1999. — Vol.83 (4). — P.486−490.
- Malkowicz S. The application of human complement factor H-related protein (BTA TRAK) in monitoring patients with bladder cancer. // J Urologic Clinics of North America. 2000. — Vol.27. — P.63−73.
- Marrink J., Oosterom R., Bonfrer H. et al. Tissue polypeptide-specific antigen: a discriminative parameter between prostate cancer and benign prostatic hypertrophy. // European J Cancer. 1993. — Vol. 29A. — P.570−571.
- Mazurek S., Grimm H., Oehme M. et al. Tumor M2-PK and glutaminolytic enzymes in the metabolic schift of tumor cell. // Anticancer Research. 2000. -Vol. 20.-P.5151−5154.
- Meier W., Stieber P., Fateh-Mohadam A. et al. Erfahrungen mit CA 125 als tumor marker bei gynakologishen malignomen, speziell beim Ovarial carcinom. // Tumormarker. 1986. — P. 163−164.
- Meria P., Toubert M., Cussenot O. et al. Tumor-associated trypsin inhibitor and renal cell carcinoma. // J European Urology. 1995. — Vol.27 (3). — P.223−226.
- Mian A., Lodde A., Heitel M. et al. Comparison of qualitative assay, the UBC rapid test and BTA stat test, in the diagnosis of urotelial cell carcinoma of the bladder // J Urology. 2000. — Vol.56. — P.228−231.
- Mian A., Lodde A., Heitel M. et al. Comparison of the monoclonal UBC-ELISA test and the NMP22 ELISA test for the detection of urothelial cell carcinoma of the bladder. // J Urology. 2000. Vol.55. — P.223−226.
- Mogensen O., Mogensen В., Jakobsen A. Tumor-associated trypsin inhibitor and cancer antigen 125 in pelvic masses. // Gynecol. Oncol. 1990. — Vol.38 (2). -P. 170−174.
- Morell A., Liana В., Alvarez A. et al. С A 125 and non gynaecological benign diseases. // Int. Symp. CA 125: Ten years Later. San-remo, Itali. — 1993. -P.1717−1720.
- Mungan N., Vriesema J., Thomas C. et al. Urinary bladder cancer test: a new urinary tumor marker in the follow-up of superficial bladder cancer. // J Urology. -2000. Vol.56. — P.787−792.
- Nakamura Т., Hayama M., Shimada M. Expression of CA 15−3 in renal cell carcinoma. // Pathol. Int. 1995. — Vol.45 (10). — P.787−789.
- Nasuti J., Gomella L., Ismial M. et al. Utility of the BTA stat test kit for bladder cancer screening. // J Diagnostic Cytopathology. 1999. — Vol.21. — P.27−29.
- Noto К., FuJime M., Isobe H. et al. Determination of urinary CA 19−9 levels in urothelial cancer-assessment of its role in diagnosis. // Nippon Hinyokika Gakkai Zasshi. 1997. — Vol.88 (3). — P.406−413.
- Obiri N., Tandon N., Puri R. Up-regulation of intercellular adhesion molecule-1 (ICAM-1) on human renal cell carcinoma cells by interleukin-4. // Int J cancer. -1995.-Vol.61 (5). -P.635−642.
- Oremek G., Rox S., Mitrou P. et al. Tumor M2-PK levels in haematological malignancies. // Anticancer Research. 2003. — Vol.23. — P. 1135−1138.
- Oremek G., Sapoutzis N., Kramer W. et al. Value of Tumor M2 (Tu M2-PK) in patients with renal carcinoma. // Anticancer Research. 2000. — Vol.20. — P.5095−5098.
- Oremek G., Teigelkamp S., Kramer W. et al. The Pyruvate Kinase Isoenzyme Tumor M2 (Tu M2-PK) as a tumor marker for renal carcinoma. // Anticancer Research. 1999. — Vol. 19. — P.2599−2602.
- Pirtskalaishvili G., Getzenberg R., Konety B. Use of urine-based markers for detection and monitoring of bladder cancer. // J Techniques in Urology. 1999. -Vol.5.-P.179−184.
- Pirtskalaishvili G., Konety В., Getzenberg R. Update on urine-based markers for bladder cancer. How sensitive and specific are the new noninvasive tests? // J Postgraduate Medicine. 1999. — Vol.106. — P.85−86,91−94.
- Raitanen M., Tammela T. Specificity of human complement factor H-related protein test (Bard BTA stat test). // J Scandinavian Urology and Nephrology. -1999.-Vol.33.-P.234−236.
- Ramakumar S., Bhuiyan J., Besse J. et al. Comparison of screening methods in the detection of bladder cancer. // J Urology. 1999. — Vol.161. — P.388−394.
- Rodriguez-Martinez, Elscaf Barmadah S., Allende M. et al. Quantification of bladder tumor antigen (BTA trak) and its correlation with bladder cancer grade and stage. // Arch Esp Urology. 2000. — Vol.53. — P. 1−6.
- Rodriguez-Rubio F., Monreal I., Robles J. et al. TPS in prostate cancer. // Actas Urology.-1995.-Vol.19.-P.131−133.
- Roigas J., Schulze G., Raytarowski S. et al. Tumor M2 pyruvate kinase in plasma of patients with urological tumors. // Tumor Biology. 2001. — Vol.22. — P.282−285.
- Roigas J., Schulze G., Raytarowski S. et al. Tumor M2 pyruvate kinase in renal cell carcinoma. // J Urology. 2000. — Vol.39 (6). — P.554−556.
- Romanenko A., Lee C., Yamamoto S. et al. Urinary bladder lesion after the Chernobyl accident: immunohistochemical assessment of p53, proliferating cell nuclear antigen, ciclin D1 and p21 WAFl/Cipl. // Jpn Cancer Res. 1999. — Vol.90. -P.144−153.
- Sanches-Carbayo M., Herrero E., Megias J. et al. Comparative sensitivity of urinary CYFRA 21−1, urinary bladder cancer antigen, tissue polypeptide antigen and NMP 22 to detection bladder cancer. // J Urology. 1999. — Vol.162. — P. 19 511 956.
- Sanches-Carbayo M., Herrero E., Megias J. et al. Initial evaluation of the new urinary bladder cancer rapid test in the detection of transitional cell carcinoma of the bladder. // J Urology. 1999. — Vol.54. — P.656−661.
- Sanches-Carbayo M., Megias J., Molina R. UBC, a new tumor marker in the diagnosis of bladder cancer. // J Int.Oncodev. Biol.Med. 1998. — Vol.19 (2). -P.72.
- Sanches-Carbayo M., Urrutia M., Silva J. et al. Urinary tissue polypeptide-specific antigen for the diagnosis of bladder cancer. // Urology. 2000. — Vol.55. — P.526−532.
- Schneider J., Vercovsky H., Morr H. et al. Comparison of the Tumors markers Tu M2-PK, CEA, CYFRA 21−1, NSE and SCC in the diagnosis of Lung Cancer. // Anticancer Research. 2000. — Vol.20. — P.5053−5058.
- Sharma S., Zippe C., Pandrangi L. et al. Exclusion criteria enhance the specificity and positive predictive value of NMP 22 and BTA stat. // J Urology. 1999. -Vol.162.-P.53−57.
- Silen A., Rizvi S., Letocha H. et al. Evaluation of the UBC test in the urine of the healthy individuals, patients with benign disorders and urinary bladder cancer. // Oncol Rep. 1999. — Vol.7. — P.1269−1274.
- Smith S., Wheeler M., Plescia J. et al. Urine detection of surviving and diagnosis of bladder cancer. // JAMA. 2001. — Vol.285. — P.324−328.
- Sozen S., Biri H., Sinik Z. et al. Comparison of the nuclear matrix protein 22 with voided urine cytology and BTA stat test in the diagnosis of transitional cell carcinoma of the bladder. // J European Urology. 1999. — Vol.36. — P.225−229.
- Stefanovic V., Mitic-Zlatkovic M., Ignjatovic I. et al. Beta 2-microglobulin in patients with urotelial cancer. // World J Urology. 1999. — Vol.17. — P. 319−323.
- Stefanovic V., Mitic-Zlatkovic M., Ignjatovic I. et al. Tissue polypeptide antigen and carcinoembryonic antigen lack diagnostic accuracy in urothelial carcinoma. // Int J Urology and Nephrology. 1999. — Vol.31 (4). — P.443−449.
- Stefanovic V., Mitic-Zlatkovic M., Ignjftovic I. et al. Tissue polypeptide antigen and carcinoembryonic antigen lack diagnostic accuracy in urothelial carcinoma. // Int Urol Nephrol. 1999. — Vol.31. — P.443−449.
- Stenman U. Tumor-associated trypsin inhibitor. // Clin. Chem. 2002. -Vol.48 (8). P.1206−1209.
- Stenman U., Paju A., Jakobsen A. Prognostic significance of tumor-associated trypsin inhibitor in renal cell carcinoma. // Libra de Abstracts. 2001. — P. 125.
- Sugaya Y., Ochi M., Hashimoto S. et al. A case of transitional cell carcinoma of renal pelvis with extremely high serum levels of CA 19−9 and CEA. // Hyniokika Kiyo. 1997. — Vol.43 (7). — P.495−499.
- Takashi M., Schenck U., Kissel R. et al. Use of diagnostic categories in urinary cytology in comparison with the bladder tumour antigen (BTA) tast in bladder cancer patients. // J International Urology and Nephrology. 1999. — Vol.31. -P. 189−196.
- Taki Т., Honda N., Yamada Y. et al. CA 19−9-producing transitional cell carcinoma of the renal pelvis: case report. // Hyniokika Kiyo. 2001. — Vol.47 (3). -P.191−194.
- Tarle M. Serial measurements of tissue polypeptide-specific antigen (TPS), PSA and CEA serotest values in treated patients with primary and metastatic prostate cancer. // Anticancer Research. 1993. — Vol.13. — P.769−777.
- Tarle M., Frkovic-Gracio S., Kraljic I. et al. A more objective staging of advanced prostate cancer-routine recognition malignant endocrine structures: the assessment of serum TPS, PSA values. // Prostate. 1994. — Vol.24. — P.143−148.
- Tarle M., Kovacic K., Kastelan M. Correlation of cell proliferation marker (TPS), natural killer (NK) activity tumor load serotest (PSA) in unteated and prostatic tumors. // Anticancer Research. 1993. — Vol.13. — P.215−218.
- Theyer G., Durer A., Theyer U. et al. Measurements of free and total PSA, tissue polypeptide-specific antigen (TPS) and CYFRA 21−1 in prostate cancer patients under intermittent androgen supperession therapy. // Prostate. 1999. — Vol.41. -P.71−77.
- Theyer G., Holub S., Durer A. et al. Measurements of tissue polypeptide-specific antigen and prostate-specific antigen in prostate cancer patients under intermittent androgen supperession therapy. // Br J Cancer. 1997. — Vol.75. — P.1515−1518.
- Thomas L., Leyh H., Marberger M. et al. Multicenter trial of the quantitative BTA TRAK assay in the detection of bladder cancer. // Clin Chem. 1999. — Vol.45. -P.472−477.
- Tozuka К., Yonese Y., Nakagami Y et al. Evaluation of serum tissue polypeptide antigen (TPA) in patients with urogenital cancer. // Gan To Kagaku Ryoho. 1984. -Vol.11 (5).-P.1078−1083.
- Wechsel H., Petri E., Bichler K. et al. Marker for renal carcinoma (RCC): the dimeric form of pyruvate kinase type M2 (Tu M2-PK). // Anticancer Research. -1999. Vol.19. — P.2583−2590.
- William A. PSA changes in early prostate cancer: implications for patient management. // European Urology Supplements. 2002. — Vol.1. — P. 17−23.
- Wolff J., Borchers H., Brehmer B. et al. Cytokeratin 8/18 levels in patients with prostate cancer and benign prostatic hypertrophy. // J Int Urology. 1998. — Vol.60. -P.152−155.
- Wolff J., Borchers H., Brehmer B. et al. Cytokeratin markers in patients with prostatic diseases. // Anticancer Research. 1999. — Vol.19. — P.2649−2652.
- Wolff J., Rohde D., Borchers H. et al. Tissue polypeptide-specific antigen serum concentrations in patients with diagnosed prostatic diseases. // Anticancer Research. 2000. — Vol.20. — P.5003−5005.
- Yamazaki K., Kumamoto Y., Tsukamoto T. et al. Immunosuppressive acidic protein (IAP) and immunosuppressive substance (ISS) in patients with renal cell carcinoma. // Hinyokika Kiyo. 1991. — Vol.37 (5). — P.467−474.